Comparison of two lab-scale protocols for enhanced mRNA-based CAR-T cell generation and functionality.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
24 10 2023
24 10 2023
Historique:
received:
21
03
2023
accepted:
17
10
2023
medline:
30
10
2023
pubmed:
25
10
2023
entrez:
24
10
2023
Statut:
epublish
Résumé
Process development for transferring lab-scale research workflows to automated manufacturing procedures is critical for chimeric antigen receptor (CAR)-T cell therapies. Therefore, the key factor for cell viability, expansion, modification, and functionality is the optimal combination of medium and T cell activator as well as their regulatory compliance for later manufacturing under Good Manufacturing Practice (GMP). In this study, we compared two protocols for CAR-mRNA-modified T cell generation using our current lab-scale process, analyzed all mentioned parameters, and evaluated the protocols' potential for upscaling and process development of mRNA-based CAR-T cell therapies.
Identifiants
pubmed: 37875523
doi: 10.1038/s41598-023-45197-x
pii: 10.1038/s41598-023-45197-x
pmc: PMC10598065
doi:
Substances chimiques
Receptors, Chimeric Antigen
0
Cytokines
0
Receptors, Antigen, T-Cell
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
18160Informations de copyright
© 2023. Springer Nature Limited.
Références
BMC Immunol. 2021 Jul 3;22(1):43
pubmed: 34217218
Front Bioeng Biotechnol. 2022 Jun 22;10:797440
pubmed: 35814023
Exp Hematol Oncol. 2020 Dec 2;9(1):34
pubmed: 33292660
Semin Hematol. 2020 Apr;57(2):33-38
pubmed: 32892841
Gastroenterology. 2018 Jul;155(1):29-32
pubmed: 29567081
Cancers (Basel). 2020 Sep 09;12(9):
pubmed: 32916883
Eur J Immunol. 1987 Jul;17(7):991-7
pubmed: 3038564
Cancer Immunol Immunother. 2014 Oct;63(10):999-1008
pubmed: 24938475
Mol Ther Methods Clin Dev. 2017 Nov 07;8:65-74
pubmed: 29687031
J Immunother Cancer. 2022 Sep;10(9):
pubmed: 36096530
Methods Mol Biol. 2020;2086:87-117
pubmed: 31707670
Front Immunol. 2020 Aug 11;11:1770
pubmed: 32849635
Front Immunol. 2019 Oct 10;10:2361
pubmed: 31649672
Front Immunol. 2022 Apr 13;13:876339
pubmed: 35493513
Front Immunol. 2022 Mar 24;13:839783
pubmed: 35401506
Int J Mol Sci. 2020 Sep 06;21(18):
pubmed: 32899932
Nat Commun. 2022 Sep 5;13(1):5225
pubmed: 36064867
Cytotherapy. 2009;11(7):936-46
pubmed: 19903105
Mol Ther Methods Clin Dev. 2020 Dec 25;20:379-388
pubmed: 33575430
Nature. 2016 Sep 14;537(7620):433-5
pubmed: 27629646
Mol Cancer. 2021 Mar 3;20(1):48
pubmed: 33658037
Cytotherapy. 2021 Nov;23(11):985-990
pubmed: 34538575
Transfusion. 2017 May;57(5):1133-1141
pubmed: 28236305
Hum Gene Ther Methods. 2016 Dec;27(6):209-218
pubmed: 27897048
Curr Res Transl Med. 2023 Apr-Jun;71(2):103385
pubmed: 36773434
In Vitro Cell Dev Biol Anim. 2018 Sep;54(8):559-566
pubmed: 30003447
Cancers (Basel). 2019 Aug 16;11(8):
pubmed: 31426437